Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00518219
Status:
COMPLETED
Last Update Posted:
2010-05-27
First Post:
2007-08-16
Brief Title:
To Compare the Efficacy and Safety of Tripterygium Wilfordii TW Versus Valsartan in the Membranous Nephropathy MN
Sponsor:
Nanjing University School of Medicine
Organization:
Nanjing University School of Medicine
Study Overview
Official Title:
To Compare the Efficacy and Safety of TW vs Valsartan in the MN
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the efficacy of TW compared to Valsartan in treatment of heavy proteinuria of membranous nephropathy
Detailed Description:
Membranous nephropathy with heavy proteinuria have high risks of progressing to CRF
Tripterygium TW is a Chinese traditional patent drugs it can reduce proteinuria of chronic glomerular nephritissuch as IgA nephropathy So we designed this randomized prospective clinical trial to assess the efficacy and safety of TW versus Valsartan in the treatment of heavy proteinuria of MN
Tripterygium TW is a Chinese traditional patent drugs it can reduce proteinuria of chronic glomerular nephritissuch as IgA nephropathy So we designed this randomized prospective clinical trial to assess the efficacy and safety of TW versus Valsartan in the treatment of heavy proteinuria of MN
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None